key: cord-0898123-mi8o0x07 authors: Singh, Awadhesh Kumar; Singh, Akriti; Singh, Ritu; Misra, Anoop title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19() date: 2022-01-13 journal: Diabetes Metab Syndr DOI: 10.1016/j.dsx.2022.102396 sha: b2b3f4554153b4bf8c0c6c68d73433b6fc531644 doc_id: 898123 cord_uid: mi8o0x07 BACKGROUND AND AIMS: Molnupiravir is a newer oral antiviral drug that has recently received emergency use authorization (EUA) in USA, UK and India. We aim to conduct an update on our previous systematic review to provide practical clinical guideline for using molnupiravir in patients with COVID-19. METHODS: We systematically searched the electronic database of PubMed, MedRxiv and Google Scholar until January 5, 2022, using key MeSH keywords. RESULTS: Final result of phase 3 study in 1433 non-hospitalized COVID-19 patients showed a significant reduction in composite risk of hospital admission or death (absolute risk difference, −3.0% [95% confidence interval {CI}, −5.9 to −0.1%]; 1-sided P = 0.02) although with a non-significant 31% relative risk reduction (RRR). RRR for death alone was 89% (95% CI, 14 to 99; P-value not reported). Number needed to treat to prevent 1 death or 1 hospitalization or death composite appears to be closely competitive to other agents having EUA in people with COVID-19. However, cost-wise molnupiravir is comparatively cheaper compared to all other agents. CONCLUSION: Molnupiravir could be a useful agent in non-pregnant unvaccinated adults with COVID-19 who are at increased risk of severity including hospitalization. However, it is effective only when used within 5-days of onset of symptoms. A 5-days course seems to be safe without any obvious short-term side effects. Majority of patients suffering from coronavirus disease 2019 (COVID-19) caused by severe respiratory syndrome coronavirus-2 (SARS-CoV-2) generally recover from acute infection with least medical interventions [1] . However, clinical progression to severe disease leading to hospitalization causes a considerable impact on patients' health (including morbidity and mortality) and healthcare systems. Thus, reducing hospitalizations (all-cause or COVID-19-associated) and death remains the most critical component of the ongoing pandemic. From the available medical interventions for COVID-19, vaccination remains the most important tool in reducing the risk of hospitalization and death [1] [2] [3] . Few other options are also found to cut this risk if started early, soon after the onset of symptoms [4] . Three monoclonal antibodies (MABs) such as cocktail of casirivimab-imdevimab (REGEN-COV TM ), and bamlanivimab-etesevimab, and single monoclonal sotrovimab [5] [6] [7] have been currently authorized for emergency use (EUA) by the United States Federal Drug Administration (FDA) for the outpatient treatment of mild to moderate COVID-19 in patients ≥12 years of age (weighing ≥40 kg) with laboratory-confirmed SARS-CoV-2 infection and, at high risk for progressing to severe COVID-19 and/or hospitalization. Casirivimab (1200 mg) and imdevimab (1200 mg) were authorized to be administered together on November 21, 2020 (the authorized dose was subsequently changed to casirivimab (600 mg) and imdevimab (600 mg). Bamlanivimab (700 mg) and etesevimab (1400 mg) were authorized to be administered together on February 9, 2021. Notably, initially bamlanivimab (700 mg) was authorized for emergency use as monotherapy on November 9, 2020, however the authorization was subsequently revoked on April 16, 2021, due to a sustained increase in variants resistant to bamlanivimab alone resulting in increased risk for treatment failure. Sotrovimab was authorized on May 26, 2021. However, these MAB therapies must be administered by intravenous infusion and/or J o u r n a l P r e -p r o o f subcutaneous injection and patients must be monitored through at least 1 hour following infusion for purported hypersensitivity (infusion-related reactions including anaphylaxis) reactions. This limits the use of MABs in outpatients setting for the majority of people with COVID-19, compounded further the limited availability of these drugs outside their country of origin and their diminished effectiveness over the emerging newer strains of SARS-CoV-2. A recent study that evaluated the sensitivity of the delta variant to the humoral immune response found that some MAB targeting the N-terminal and receptor binding domains of the spike protein had impaired binding and neutralization [8] . This suggests that some of these MAB therapies may be less effective to new SARS-CoV-2 variants having mutations in the spike protein [9] . Indeed, bamlanivimab-etesevimab has >45-fold decreased susceptibility against Beta (B.1.351) and >511-fold decreased susceptibility against Gamma (P.1) SARS-CoV-2 variants of concern (VOC) [10, 11] . Notably, against new VOC, Omicron (B.1.1.529) neutralizing potency of both bamlanivimab-etesevimab and casirivimab-imdevimab were greatly reduced although sotrovimab has been found to still function with reduced efficacy [12] . Indeed, the only anti-viral drug that has been licensed by FDA is remdesivir for use in both adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of COVID-19 requiring hospitalization. However, remdesivir also require administration by means of infusion or injection in a medical setting with frequent monitoring. To overcome some of these issues, two new oral anti-viral agents have been recently developed that can be administered by the patient at home shortly after the diagnosis. Importantly, while paxlovid TM is currently available in USA, molnupiravir has been made available in majority of countries across the world including India from first week of January 2022. Aim of this paper is to update our recently conducted systematic review of molnupiravir (data complied until October 15, 2021) [13] and to provide some practical tips and tricks of using molnupiravir for COVID-19 patients by raising few contemporary questions. Additionally, we also evaluated effectiveness of molnupiravir compared to other drugs having EUA for COVID-19. We searched the electronic data base of PubMed, MedRxiv and Google Scholar to find additional data of molnupiravir that has become available between October 15, 2021, until Jan 5, 2022. We also accessed the data of molnupiravir presented at FDA Antimicrobial Drugs Advisory Committee (AMDAC) meeting on November 30, 2021. Moreover, we accessed the prescribing information of molnupiravir by FDA (USA), MHRA (UK) and CDSCO (India). Furthermore, we searched the studies conducted with 3 MABs (casirivimab-imdevimab, bamlanivimab-etesevimab, sotrovimab), nirmatrelvir-ritonavir and remdesivir in people with COVID-19. We found full published results of phase 3, double-blind, randomized study (MOVe-OUT) that was planned to assess efficacy and safety of molnupiravir in 1433 non-J o u r n a l P r e -p r o o f hospitalized adult (18 years or older) participants with COVID-19 (NCT04575597, MK-4482-002) [14] . It should be recalled that an interim analysis (n = 775) of MOVe-OUT study that found a significant relative risk reduction of 52% (95% confidence interval [CI], 33 to 80; 1-sided p = 0.0012) for hospital admission or death through day 29 was stopped by the independent data safety monitoring board due to excessive benefit in molnupiravir arm compared to the placebo. Intriguingly, in the full results from 1433 participant the relative risk reduction for hospitalization or death fell to 31% (Hazard ratio [HR] 0.69; 95% CI, 0.48 to 1.01) through day 29 [14] . Another development that took place recently was on November 30, 2021, an FDA advisory panel recommended the agency to grant EUA of molnupiravir in mild to moderate COVID-19 with at least one risk factor by a narrow 13-10 vote margin [15] . FDA announced EUA for molnupiravir on December 23, 2021. To note, Kingdom was the first in the world to conditionally authorize molnupiravir on November 4, 2021, based on interim analysis of MOVe-OUT study [16] . Table 1 summarizes the findings from MOVe-OUT study and FDA AMDAC meeting. It is important to know, how to use molnupiravir in people with COVID-19. Molnupiravir can be taken orally with for without food. No The use of molnupiravir is not recommended during pregnancy. When considering molnupiravir for a pregnant individual, the prescribing healthcare provider must communicate the known and potential benefits and the potential risks of using Most common (incidence ≥ 1%) adverse reactions observed are diarrhea, nausea, and dizziness but it is similar to placebo [17, 18]. Since significant bone marrow toxicity was reported in a 28-day toxicology study in Based on the findings in rats, use of molnupiravir during pregnancy is not recommended and use of contraception in individuals of child-bearing potential is advised for the duration of NHC systemic exposure (during treatment and for the 4 days following completion). J o u r n a l P r e -p r o o f The incidence of hospitalization or death in modified intention-to-treat (m-ITT) interim analysis of both interim (7.3 vs. 14.1% in molnupiravir vs. placebo, respectively) and all-randomized participants (6.9 vs. 9.7% in molnupiravir vs. placebo, respectively) were consistent in the molnupiravir group vs. placebo but fell in the post interim population of placebo arm (6.2 vs. 4.7% in molnupiravir vs. placebo, respectively) compared to the placebo group of interim population ( Table 1 ). While the exact reasons for this difference in outcome are unknown, potential contributing factors may include-baseline imbalances in the two arms, regional variations in the severity of enrolled participants and different hospitalization practices and shifts in the epidemiology of the COVID-19 pandemic amongst newly enrolling participating countries. Indeed, in the interim analysis sample, more women were randomly assigned to molnupiravir (difference, 7.6%) than in the allrandomized sample (difference, 4.7%). However, more female patients (purportedly who have a lower risk of severe COVID-19 than male patients), more participants with SARS-CoV-2 nucleocapsid antibodies suggestive of recent or past infection (suggests a lower risk), and more participants with low viral load at baseline (in whom there is less virologic effect) were recruited in the placebo group of allrandomized sample compared to the interim analysis sample ( Table 2 ). All these factors may have contributed to a lower overall event rate in the placebo group in the all-randomized sample than in the interim analysis [14] . hospitalization or death through day 29 were lower in molnupiravir vs. placebo (7.3% vs. 14.1%, respectively) group. These heterogeneity in outcomes appeared to be the reason of diminished effectiveness in all-population analysis. It should be noted that while composite of hospitalization or death decreased to nearly 30%, a relative risk reduction of 89% (95% CI, 14% to 99%) in death through day 29 were noted in molnupiravir arm compared to placebo in full analysis (Table 1) . In most prespecified subgroups, the percentage of participants who were hospitalized or died were lower with molnupiravir than placebo, however the Caveat for these subgroups who had no benefit with molnupiravir was based on small sample size, lesser number of events with imprecise (fairly wide) point estimates when associated 95% confidence intervals included zero ( Table 3) . Vaccination status could be considered as one of the potential patient selection criteria. Vaccinated individuals were excluded from MOVe-OUT study (MK-4482-002), thus effect of molnupiravir in breakthrough infections is not known. Since the risk of hospitalization and death among fully vaccinated individuals is known to be significantly lower than the risk among unvaccinated individuals, role of molnupiravir is expected to be limited and hence should be avoided in our opinion unless benefit to risk ratio is in favor of molnupiravir. No significant effect of molnupiravir in reducing hospitalization or death in people who had positive nucleocapsid antibody (20% at baseline) suggestive of recent or past SARS-CoV-2 infection, suggests avoiding its use unless benefit to risk ratio is in favor of molnupiravir. 55% of samples of confirmed COVID-19 from the molnupiravir MOVe-OUT study were sequenced, of which 58% had delta (B.1.617.2), 20% had Mu (B.1.621), 11% had Gamma (P.1) and 3% each were of alpha and lambda strain. 44% had missing sequence data. Subgroup analysis found molnupiravir was effective irrespective of strain although no data is available for its effect on Omicron in particular [14] . Unlike MABs, the mechanism of action of molnupiravir is independent of mutations in the spike protein, and thus it is expected to work against Omicron, theoretically All 3 MABs, remdesivir, nirmatrelvir plus ritonavir and molnupiravir have been studied in mild-to-moderate COVID-19 against placebo [28] [29] [30] [31] [32] . Table 4 summarizes the comparative efficacy of all these drugs. Notably, these are not headto-head studies comparing these agents and primary objective were slightly different. Collectively, from the available evidence currently available, molnupiravir appears to be reasonably useful agent in reducing death and composite of hospitalization or death in adult patients with COVID-19 having high risk, with a relatively lower cost. unlikely to have any long-term major concern on individual patient level, inappropriate and injudicious use in too many individuals without assessing risk: benefit ratio may pose an unknown long-term risk of theoretical public concern. Thus, use molnupiravir carefully and judiciously. Box 5 summarizes some useful tips and tricks of using molnupiravir in non-pregnant adult patients with COVID-19 with high risk for severity including hospitalization. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network -United States New COVID-19 cases and hospitalizations among adults, by vaccination status Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalization -five veterans affairs medical centers Neutralizing antibody therapeutics for COVID-19 Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization Risk assessment: SARSCoV-2 -increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab and etesevimab Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies Molnupiravir in COVID-19: A systematic review of literature Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients FDA Okays Emergency Use of Molnupiravir Pill for COVID-19 (medscape.com) Accessed on Regulatory approval of Lagevrio (molnupiravir) -GOV.UK (www.gov.uk) Fact sheet for healthcare providers: emergency use authorization for molnupiravir (fda.gov). accessed on Fact sheet for healthcare professionals: restricted emergency use for molnupiravir in India (prescribing information for molcovir by Optimus pharma). 19. C1530_Interim-clinical-commissioning-policy-neutralising-monoclonal-Active arm event P-value 70% *